Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

Toshiyuki Sawa,Takashi Yana,Minoru Takada,Takahiko Sugiura,Shinzoh Kudoh,Tadashi Kamei,Takeshi Isobe,Hidehiko Yamamoto,Soichiro Yokota,Nobuyuki Katakami,Yuji Tohda,Akira Kawakami,Yoichi Nakanishi,Yutaka Ariyoshi

Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

2006

Toshiyuki Sawa
Takashi Yana
Minoru Takada
Takahiko Sugiura
Shinzoh Kudoh
Tadashi Kamei
Takeshi Isobe
Hidehiko Yamamoto
Soichiro Yokota
Nobuyuki Katakami
Yuji Tohda
Akira Kawakami
Yoichi Nakanishi
Yutaka Ariyoshi

Purpose: Amrubicin is a novel 9-aminoanthracycline. This multicenter phase II study was conducted to evaluate the efficacy and safety of amrubicin in patients with non-small-cell lung cancer (NSCLC).

Keywords:

Anesthesia
Oncology
Performance status
Phases of clinical research
Amrubicin
Thoracic Oncology
Lung cancer
Anthracycline
Surgery
Medicine
Internal medicine
non small cell
pharmacology toxicology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations